These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 1389748)

  • 1. Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.
    O'Brien BJ; Buxton MJ; Rushby JA
    Br Heart J; 1992 Aug; 68(2):241-5. PubMed ID: 1389748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.
    Owens DK; Sanders GD; Heidenreich PA; McDonald KM; Hlatky MA
    Am Heart J; 2002 Sep; 144(3):440-8. PubMed ID: 12228780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS).
    O'Brien BJ; Connolly SJ; Goeree R; Blackhouse G; Willan A; Yee R; Roberts RS; Gent M
    Circulation; 2001 Mar; 103(10):1416-21. PubMed ID: 11245646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy.
    Larsen GC; Manolis AS; Sonnenberg FA; Beshansky JR; Estes NA; Pauker SG
    J Am Coll Cardiol; 1992 May; 19(6):1323-34. PubMed ID: 1564234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence rather than costs must guide use of the implantable cardioverter defibrillator.
    Delacretaz E; Schlaepfer J; Metzger J; Fromer M; Kappenberger L
    Am J Cardiol; 2000 Nov; 86(9A):52K-57K. PubMed ID: 11084101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death.
    Spath MA; O'Brien BJ
    Pharmacoeconomics; 2002; 20(11):727-38. PubMed ID: 12201792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death.
    Owens DK; Sanders GD; Harris RA; McDonald KM; Heidenreich PA; Dembitzer AD; Hlatky MA
    Ann Intern Med; 1997 Jan; 126(1):1-12. PubMed ID: 8992917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study.
    Sheldon R; O'Brien BJ; Blackhouse G; Goeree R; Mitchell B; Klein G; Roberts RS; Gent M; Connolly SJ
    Circulation; 2001 Oct; 104(14):1622-6. PubMed ID: 11581139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
    Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
    Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
    Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
    Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
    Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant amiodarone and the implantable cardioverter-defibrillator: is there a place?
    McCollam PL; Nappi JM
    Ann Pharmacother; 1993 Jun; 27(6):736-41. PubMed ID: 8329797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study.
    Wever EF; Hauer RN; Schrijvers G; van Capelle FJ; Tijssen JG; Crijns HJ; Algra A; Ramanna H; Bakker PF; Robles de Medina EO
    Circulation; 1996 Feb; 93(3):489-96. PubMed ID: 8565166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.